《新股消息》據報億騰醫藥啓動預路演 集資3億美元
據路透旗下《IFR》引述消息指,內地綜合醫藥公司億騰醫藥已啓動預路演活動,以評估投資者意向,預期集資約3億美元。聯席保薦人爲摩根士丹利及瑞信。
聯交所初步文件顯示,億騰醫藥專注於抗感染、心血管疾病及呼吸系統三個核心治療領域,目前擁有6種核心產品,並以合同銷售組織(CSO)模式爲跨國公司擔任獨家營銷商及分銷商。
於2020年度公司錄收入17.67億元人民幣,按年跌5.7%,純利亦跌37.9%至9,399.2萬元人民幣。億騰醫藥上市前投資者包括OrbiMed Asia、紅杉資本、浦銀國際等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.